Skip to content

Spyre Therapeutics

US · SYRE #1646 by market cap Listed 1970
93.47 -4.16 -4.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 10.91 Expensive vs history 94th percentile
5-year average -56.40 · #463 of 514 in Biotechnology
P/E ratio -37.41 Cheap vs history 8th percentile
5-year average -8.58 · forward -24.16
P/S ratio 14,355.81 Expensive vs history 100th percentile
5-year average 2,352.49 · #381 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Spyre Therapeutics (SYRE) 8.88B -33.62 9.81 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value105.87 Economic moatNone UncertaintyHigh

Trading 13.3% below Morningstar's fair value estimate.

Fair value

Spyre Therapeutics Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 2% discount to our quantitative fair value estimate of $105.87 per share; however, caution is warranted due to this estimate's high uncertainty rating.

We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Spyre Therapeutics discussion 0 comments

Add a comment